Contemporary Pediatric Heart Transplant Waitlist Mortality

• Published in: Journal of the American College of Cardiology Vol. 84; no. 7; pp. 620 - 632
• Main Authors: Power, Alyssa, Sweat, Kurt R., Roth, Alvin, Dykes, John C., Kaufman, Beth, Ma, Michael, Chen, Sharon, Hollander, Seth A., Profita, Elizabeth, Rosenthal, David N., Barkoff, Lynsey, Chen, Chiu-Yu, Davies, Ryan R., Almond, Christopher S.
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 13.08.2024
• Subjects: heart; pediatrics; survival; transplantation; VAD; waitlist mortality; ECMO; PP; survival; HT; heart; LVAD; DCM; waitlist mortality; HCM; pediatrics; transplantation; VAD; ABO-I; UNOS; RCM; CHD; OPTN
• ISSN: 0735-1097; 1558-3597; 1558-3597
• DOI: 10.1016/j.jacc.2024.05.049

In 2016, the United Network for Organ Sharing revised its pediatric heart transplant (HT) allocation policy. This study sought to determine whether the 2016 revisions are associated with reduced waitlist mortality and capture patient-specific risks. Children listed for HT from 1999 to 2023 were identified using Organ Procurement and Transplantation Network data and grouped into 3 eras (era 1: 1999-2006; era 2: 2006-2016; era 3: 2016-2023) based on when the United Network for Organ Sharing implemented allocation changes. Fine-Gray competing risks modeling was used to identify factors associated with death or delisting for deterioration. Fixed-effects analysis was used to determine whether allocation changes were associated with mortality. Waitlist mortality declined 8 percentage points (PP) across eras (21%, 17%, and 13%, respectively; P < 0.01). At listing, era 3 children were less sick than era 1 children, with 6 PP less ECMO use (P < 0.01), 11 PP less ventilator use (P < 0.01), and 1 PP less dialysis use (P < 0.01). Ventricular assist device (VAD) use was 13 PP higher, and VAD mortality decreased 9 PP (P < 0.01). Non-White mortality declined 10 PP (P < 0.01). ABO-incompatible listings increased 27 PP, and blood group O infant mortality decreased 13 PP (P < 0.01). In multivariable analyses, the 2016 revisions were not associated with lower waitlist mortality, whereas VAD use (in era 3), ABO-incompatible transplant, improved patient selection, and narrowing racial disparities were. Match-run analyses demonstrated poor correlation between individual waitlist mortality risk and the match-run order. The 2016 allocation revisions were not independently associated with the decline in pediatric HT waitlist mortality. The 3-tier classification system fails to adequately capture patient-specific risks. A more flexible allocation system that accurately reflects patient-specific risks and considers transplant benefit is urgently needed.